The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment
Open accessAbstract
Opioid overdoses, many of which are attributed to use of illicit fentanyl, are currently one of the leading causes of death in the U.S. Although fentanyl has been used safely for decades in clinical settings, the widespread use of illicit fentanyl is a recent phenomenon. Starting in 2013, illicitly manufactured fentanyl and its analogs began to appear on the streets. These substances were added to or sold as heroin, often unbeknownst to the user. Because fentanyl is so potent, only small amounts are needed to produce pharmacological effects, but the margin between safe and toxic doses is narrow. Surprisingly little is known about the exact signaling mechanisms underlying fentanyl-related respiratory depression or the effectiveness of naloxone in reversing this effect. Similarly, little is known about the ability of treatment medications such as buprenorphine, methadone, or naltrexone to reduce illicit fentanyl use. The present article reviews the receptor, preclinical and clinical pharmacology of fentanyl, and how its pharmacology may predict the effectiveness of currently approved medications for treating illicit fentanyl use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schinkel, A. H., Wagenaar, E., Mol, C. A., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,264
Enhanced Morphine Analgesia in Mice Lacking β-Arrestin 2
Bohn, L. M., Lefkowitz, R. J., Gainetdinov, R. R., Peppel, K., Caron, M. G., & Lin, F.-T. (1999) · Science · doi:10.1126/science.286.5449.2495 · Cited by 1,077
Structure-based discovery of opioid analgesics with reduced side effects
Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D., Corder, G., Levit, A., Kling, R. C., Bernat, V., Hübner, H., et al. (2016) · Nature · doi:10.1038/nature19112 · Cited by 944
μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence
Bohn, L. M., Gainetdinov, R. R., Lin, F.-T., Lefkowitz, R. J., & Caron, M. G. (2000) · Nature · doi:10.1038/35047086 · Cited by 927
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance
Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., von Zastrow, M., Schulz, S., Koch, T., Evans, C. J., & Christie, M. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005942 · Cited by 802
Morphine Side Effects in β-Arrestin 2 Knockout Mice
Raehal, K. M., Walker, J. K. L., & Bohn, L. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087254 · Cited by 626
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567 · cited 4×
“Note, the reduced abuse potential with prior pain to opioid exposure may not apply to individuals with comorbidities of posttraumatic stress disorder, depression and anxiety or the presence of catastrophizing (Evans & Cahill, 2016). by GTPγS binding in cells expressing mouse or human MORs (Schmid et al., 2017).”
BackgroundInfluentialFishbain, D. A., Cole, B., Lewis, J., Rosomoff, H. L., & Rosomoff, R. S. (2008) · Pain Medicine · doi:10.1111/j.1526-4637.2007.00370.x · Cited by 565
Traynor, J. R., & Nahorski, S. R. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08634-1 · Cited by 462
Trends in Abuse of OxyContin® and Other Opioid Analgesics in the United States: 2002-2004
Cicero, T. J., Inciardi, J. A., & Muñoz, A. (2005) · The Journal of Pain · doi:10.1016/j.jpain.2005.05.004 · Cited by 461
Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs
Volpe, D. A., Tobin, G. A. M., Mellon, R. D., Katki, A. G., Parker, R. J., Colatsky, T., Kropp, T. J., & Verbois, S. L. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.12.007 · Cited by 446
Persistent Increase in the Motivation to Take Heroin in Rats with a History of Drug Escalation
Ahmed, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00133-5 · Cited by 364
Naloxone dosage for opioid reversal: current evidence and clinical implications
Rzasa Lynn, R., & Galinkin, J. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617744161 · Cited by 346
Labroo, R. B., Paine, M. F., Thummel, K. E., & Kharasch, E. D. (1997) · PubMed · Cited by 291
Characteristics of Fentanyl Overdose — Massachusetts, 2014–2016
Somerville, N. J., O’Donnell, J., Gladden, R. M., Zibbell, J. E., Green, T. C., Younkin, M., Ruiz, S., Babakhanlou-Chase, H., Chan, M., Callis, B. P., et al. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6614a2 · Cited by 288
Fairbairn, N., Coffin, P. O., & Walley, A. Y. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.06.005 · Cited by 274
Controversies in translational research: drug self-administration.
Haney, M., & Spealman, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1079-x · Cited by 270
Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human
Morgan, M. M., & Christie, M. J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01335.x · Cited by 270
Toxicity Associated With Long-term Intravenous Heroin and Cocaine Self-administration in the Rat
Bozarth, M. A. (1985) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1985.03360010087032 · Cited by 261
Groer, C. E., Tidgewell, K., Moyer, R. A., Harding, W. W., Rothman, R. B., Prisinzano, T. E., & Bohn, L. M. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.028258 · Cited by 224
Wandel, C., Kim, R., Wood, M., & Wood, A. (2002) · Anesthesiology · doi:10.1097/00000542-200204000-00019 · Cited by 215
The history and development of the fentanyl series
Stanley, T. H. (1992) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(92)90047-l · Cited by 214
The Effect of Intrinsic Efficacy on Opioid Tolerance
Duttaroy, A., & Yoburn, B. C. (1995) · Anesthesiology · doi:10.1097/00000542-199505000-00018 · Cited by 214
Behavioral economics: a novel experimental approach to the study of drug dependence
Bickel, W. K., DeGrandpre, R. J., & Higgins, S. T. (1993) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(93)90059-y · Cited by 212
Bickel, W. K., DeGrandpre, R. J., & Higgins, S. T. (1995) · Psychopharmacology · doi:10.1007/bf02245952 · Cited by 198
Principles of initial experimental drug abuse liability assessment in humans
Griffiths, R. R., Bigelow, G. E., & Ator, N. A. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00098-x · Cited by 190
Raehal, K. M., & Bohn, L. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.08.003 · Cited by 189
Guidelines and methodological reviews concerning drug abuse liability assessment
Balster, R. L., & Bigelow, G. E. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00097-8 · Cited by 170
Abuse Liability of Prescription Opioids Compared to Heroin in Morphine-Maintained Heroin Abusers
Comer, S. D., Sullivan, M. A., Whittington, R. A., Vosburg, S. K., & Kowalczyk, W. J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301479 · Cited by 165
Self-citationOpiate self-administration as a measure of chronic nociceptive pain in arthritic rats
Colpaert, F. C., Tarayre, J. P., Aliaga, M., Slot, L. A. B., Attal, N., & Koek, W. (2001) · Pain · doi:10.1016/s0304-3959(00)00413-9 · Cited by 153
The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine
Chen, J., Smith, E. R., Cahill, M., Cohen, R., & Fishman, J. B. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90152-s · Cited by 153
Compulsive-Like Responding for Opioid Analgesics in Rats with Extended Access
Wade, C. L., Vendruscolo, L. F., Schlosburg, J. E., Hernandez, D. O., & Koob, G. F. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.188 · Cited by 152
Behavioral economics of drug self-administration: an introduction
Hursh, S. R. (1993) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(93)90058-x · Cited by 147
Pharmacokinetics of Non-Intravenous Formulations of Fentanyl
Lötsch, J., Walter, C., Parnham, M. J., Oertel, B. G., & Geißlinger, G. (2012) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0016-7 · Cited by 144
Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors
Maguire, P. A., Tsai, N. F., Kamal, J., Cometta–Morini, C., Upton, C., & Loew, G. H. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90685-w · Cited by 141
Paronis, C. A., & Holtzman, S. G. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10719-2 · Cited by 134
Negus, S. S. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.095380 · Cited by 133
Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse?
Burns, G., DeRienz, R. T., Baker, D. D., Casavant, M., & Spiller, H. A. (2016) · Clinical Toxicology · doi:10.3109/15563650.2016.1157722 · Cited by 126 · cited 2×
“While it is well known that fentanyl, like other opioid agonists, produces respiratory depression primarily via activation of opioid receptors in the pre-Bötzinger complex as well as actions in the Kolliker-Fuse and parabrachial nuclei of the pons (Lalley, 2006), recent clinical studies have also demonstrated that fen…”
BackgroundHipólito, L., Wilson‐Poe, A. R., Campos‐Jurado, Y., Zhong, E., González-Romero, J. L., Virag, L., Whittington, R. A., Comer, S. D., Carlton, S. M., Walker, B. M., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1053-15.2015 · Cited by 125
Self-citationAcute Intoxications and Fatalities From Illicit Fentanyl and Analogues: An Update
Pichini, S., Solimini, R., Berretta, P., Pacifici, R., & Busardò, F. P. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000465 · Cited by 122
Martin, T. J., Kim, S. A., Buechler, N. L., Porreca, F., & Eisenach, J. C. (2007) · Anesthesiology · doi:10.1097/00000542-200702000-00020 · Cited by 109
G‐protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal
Terman, G. W., Jin, W., Cheong, Y. P., Lowe, J., Caron, M. G., Lefkowitz, R. J., & Chavkin, C. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705595 · Cited by 99
Chen, S. A., O'Dell, L. E., Hoefer, M. E., Greenwell, T. N., Zorrilla, E. P., & Koob, G. F. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301008 · Cited by 97 · cited 2×
“…heroin self-administration rapidly escalate their drug intake that is concomitant with development of analgesic tolerance and continued drug intake despite adverse consequences such as foot shock (Bozarth and Wise, 1985; Ahmed et al., 2000; Chen et al., 2006; Negus, 2006; Wade et al., 2015).”
BackgroundSchneider, S., Provasi, D., & Filizola, M. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00948 · Cited by 95
Addictive behaviors related to opioid use for chronic pain: A population-based study
Hjsted, J., Ekholm, O., Kurita, G. P., Juel, K., & Sjøgren, P. (2013) · Pain · doi:10.1016/j.pain.2013.07.046 · Cited by 89
Mu Opioid Receptor Activation of ERK1/2 Is GRK3 and Arrestin Dependent in Striatal Neurons
Macey, T. A., Lowe, J., & Chavkin, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604278200 · Cited by 84
Walker, E. A., & Young, A. M. (2001) · Psychopharmacology · doi:10.1007/s002130000620 · Cited by 78
Barrett, A. C., Cook, C., Terner, J. M., Craft, R. M., & Picker, M. J. (2001) · Psychopharmacology · doi:10.1007/s002130100821 · Cited by 76
Comer, S. D., Zacny, J. P., Dworkin, R. H., Turk, D. C., Bigelow, G. E., Foltin, R. W., Jasinski, D. R., Sellers, E. M., Adams, E. H., Balster, R. L., et al. (2012) · Pain · doi:10.1016/j.pain.2012.07.035 · Cited by 70
Self-citationSubjective and behavioral responses to intravenous fentanyl in healthy volunteers
Zacny, J. P., Lichtor, J. L., Zaragoza, J. G., & de Wit, H. (1992) · Psychopharmacology · doi:10.1007/bf02245155 · Cited by 69
Internet-based Survey of Nonmedical Prescription Opioid Use in the United States
Katz, N. P., Fernandez, K. C., Chang, A., Benoit, C. M., & Butler, S. F. (2008) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e318167a087 · Cited by 68
Hah, J. M., Sturgeon, J. A., Zocca, J., Sharifzadeh, Y., & Mackey, S. (2017) · Journal of Pain Research · doi:10.2147/jpr.s131979 · Cited by 68
Morphine self-administration in the rat during adjuvant-induced arthritis
Lyness, W. H., Smith, F. L., Heavner, J. E., Iacono, C. U., & Garvin, R. D. (1989) · Life Sciences · doi:10.1016/0024-3205(89)90062-3 · Cited by 66
A Unique Role of RGS9-2 in the Striatum as a Positive or Negative Regulator of Opiate Analgesia
Psigfogeorgou, K., Terzi, D., Papachatzaki, M. M., Varidaki, A., Ferguson, D., Gold, S. J., & Zachariou, V. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.4146-10.2011 · Cited by 65
A review of human drug self-administration procedures
Jones, J. D., & Comer, S. D. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283641c3d · Cited by 65
Self-citationClocinnamox: a novel, systemically-active, irreversible opioid antagonist.
Comer, S. D., Burke, T. F., Lewis, J. W., et al. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10898-7 · Cited by 65
Self-citationTolerance to morphine-like stimulus effects of mu opioid agonists.
Young, A. M., Kapitsopoulos, G., & Makhay, M. M. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24788-7 · Cited by 58
Ghoneim, M. M., Mewaldt, S. P., & Thatcher, J. (1975) · Psychopharmacology · doi:10.1007/bf00421185 · Cited by 57
Abuse liability of oxycodone as a function of pain and drug use history
Comer, S. D., Sullivan, M. A., Vosburg, S. K., Kowalczyk, W. J., & Houser, J. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.12.018 · Cited by 56
Self-citationExpression and treatment of pain-related behavioral depression
Negus, S. S. (2013) · Lab Animal · doi:10.1038/laban.255 · Cited by 53
Silicon to syringe: Cryptomarkets and disruptive innovation in opioid supply chains
Gilbert, M. K., & Dasgupta, N. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.05.052 · Cited by 53
Winger, G. D., & Woods, J. H. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00166-6 · Cited by 51
Involvement of an influx transporter in the blood–brain barrier transport of naloxone
Suzuki, T., Ohmuro, A., Miyata, M., Furuishi, T., Hidaka, S., Kugawa, F., Fukami, T., & Tomono, K. (2010) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.707 · Cited by 46
Ewan, E. E., & Martin, T. J. (2011) · Anesthesiology · doi:10.1097/aln.0b013e31820a4edb · Cited by 44
Zacny, J. P., McKay, M. A., Toledano, A. Y., Marks, S., Young, C. J., Klock, P. A., & Apfelbaum, J. L. (1996) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(96)01274-4 · Cited by 43
Effect of Chronic Pain on Fentanyl Self-Administration in Mice
Wade, C. L., Krumenacher, P., Kitto, K. F., Peterson, C. D., Wilcox, G. L., & Fairbanks, C. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079239 · Cited by 43
Greenwald, M. K., & Roehrs, T. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300596 · Cited by 41
Lalley, P. M. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00530.2005 · Cited by 41
Cicero, T. J., Ellis, M. S., & Kasper, Z. A. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.04.004 · Cited by 41
Kuhar, J. R., Bedini, A., Melief, E. J., Chiu, Y.-C., Striegel, H. N., & Chavkin, C. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.05.019 · Cited by 39
Comparative Abuse Liability of Intravenously Administered Remifentanil and Fentanyl
Baylon, G. J., Kaplan, H. L., Somer, G. R., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00002 · Cited by 39
Human studies on the μ opiate receptor agonist fentanyl: Neuroendocrine and behavioral responses
Hoehe, M., Duka, T., & Doenicke, A. (1988) · Psychoneuroendocrinology · doi:10.1016/0306-4530(88)90046-7 · Cited by 38
Altarifi, A., Rice, K. C., & Negus, S. S. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219873 · Cited by 37
Ewan, E. E., & Martin, T. J. (2011) · Anesthesiology · doi:10.1097/aln.0b013e3182330448 · Cited by 37
Contribution of ‘receptor’ affinity to analgesic potency
Terenius, L. Y. (1974) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1974.tb09245.x · Cited by 35
Sensitization and tolerance to the discriminative stimulus effects of mu-opioid agonists
Paronis, C. A., & Holtzman, S. G. (1994) · Psychopharmacology · doi:10.1007/bf02244991 · Cited by 34
Robinson, J. E., Vardy, E., DiBerto, J. F., Chefer, V. I., White, K. L., Fish, E. W., Chen, M., Gigante, E. D., Krouse, M. C., Sun, H., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.109 · Cited by 33
Mittal, N., Tan, M., Egbuta, O., Desai, N., Crawford, C. A., Xie, C.-W., Evans, C. J., & Walwyn, W. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.42 · Cited by 32
Simple devices in differentiating the effects of buprenorphine and fentanyl in healthy volunteers
Manner, T., Kanto, J., & Salonen, M. (1987) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541294 · Cited by 31
Behavioral economic analysis of drug preference using multiple choice procedure data
Greenwald, M. K. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.09.002 · Cited by 31
Narita, M., Imai, S., Nakamura, A., Ozeki, A., Asato, M., Rahmadi, M., Sudo, Y., Hojo, M., Uezono, Y., Devi, L. A., et al. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00354.x · Cited by 28
Comparative clinical pharmacology of short-acting mu opioids in drug abusers.
Greenwald, M. K., June, H. L., Stitzer, M. L., & Marco, A. P. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13068-1 · Cited by 26
Matussek, N., & Hoehe, M. R. (2008) · Neuropsychobiology · doi:10.1159/000118542 · Cited by 22
Ligeza, A., Wawrzczak‐Bargieła, A., Kamińska, D., Korostyński, M., & Przewłocki, R. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06531.x · Cited by 20
Smith, M. A., & Picker, M. J. (1998) · Psychopharmacology · doi:10.1007/s002130050739 · Cited by 18
Wang, X.-F., Barbier, E., Chiu, Y.-T., He, Y., Zhan, J., Bi, G., Zhang, H., Feng, B., Liu‐Chen, L., Wang, J. B., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0603-16.2016 · Cited by 18
Negus, S. S., Brandt, M. R., Gatch, M. B., & Mello, N. K. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00331-9 · Cited by 17
Hoehe, M. R. (1988) · Psychoneuroendocrinology · doi:10.1016/0306-4530(88)90059-5 · Cited by 17
Effects of fasting on responses to intravenous fentanyl in healthy volunteers
Zacny, J. P., Lichtor, J. L., Zaragoza, J. G., & de Wit, H. (1992) · Journal of Substance Abuse · doi:10.1016/0899-3289(92)90019-t · Cited by 16
Risk factors for addiction among patients receiving prescribed opioids: a systematic review protocol
Cragg, A., Hau, J. P., Woo, S. A., Liu, C., Doyle‐Waters, M. M., & Hohl, C. M. (2017) · Systematic Reviews · doi:10.1186/s13643-017-0642-0 · Cited by 14
Cited by
Fibromyalgia: Recent Advances in Diagnosis, Classification, Pharmacotherapy and Alternative Remedies
Maffei, M. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217877 · Cited by 150
The epidemic of fentanyl misuse and overdoses: challenges and strategies
Volkow, N. D. (2021) · World Psychiatry · doi:10.1002/wps.20846 · Cited by 89
Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated
Varshneya, N. B., Hassanien, S. H., Holt, M. C., Stevens, D. L., Layle, N. K., Bassman, J. R., Iula, D. M., & Beardsley, P. M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114805 · Cited by 62
“First, the route of administration used in this study (subcutaneous) is different from the routes commonly used by persons with OUD to consume fentanyl containing products [45].”
BackgroundNew Synthetic Opioids: Clinical Considerations and Dangers
Edinoff, A. N., Martinez Garza, D., Vining, S. P., Vasterling, M. E., Jackson, E. D., Murnane, K. S., Kaye, A. M., Fair, R. N., Torres, Y. J. L., Badr, A. E., et al. (2023) · Pain and Therapy · doi:10.1007/s40122-023-00481-6 · Cited by 61
Vasudevan, L., Vandeputte, M., Deventer, M., Wouters, E., Cannaert, A., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113910 · Cited by 55
Metadata
- Authors
- Comer, S. D., & Cahill, C. M.
- Venue
- Neuroscience & Biobehavioral Reviews
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 106
- Pages
- 49-57
- ISSN
- 0149-7634 (ISSN-L)
- OpenAlex
- W2903520456
- Cited by
- 302
- References
- 90
- FWCI
- 12.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.